K-numberK252362
Device nameGBrain MRI
ApplicantGalileo Cds, Inc.
Product codeQIH
Device classClass II
Decision dateAug 22, 2025
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

GBrain MRI is post-processing medical device software that analyzes brain MRI images to automatically segment and quantify signal hyperintensities on T2-weighted FLAIR and T1-weighted post-contrast images. It provides volumetric measurements and visual overlays to aid radiologists in quantitative assessment of structural brain MRIs in diagnostic radiology contexts, while emphasizing that physician review and clinical judgment remain essential.

Technological characteristics

Both the subject and predicate devices are software-only systems that accept DICOM-format brain MRI images as input and output volumetric measurements in DICOM format. Both use deep learning algorithms to segment hyperintensities, calculate volumes, generate colored segmentation overlays on DICOM images, and summarize results in PDF reports. The subject device extends the predicate's functionality by adding segmentation capability for contrast-enhancing regions on T1-weighted post-contrast images in addition to FLAIR images.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

The subject device shares identical intended use, intended users, environment of use, patient population, and regulatory classification (21 CFR 892.2050, Class II) as the predicate. Both perform the same core technical task—automated quantification of MR signal hyperintensity for diagnostic support—using equivalent deep-learning-based segmentation methodology. Performance testing on 131 validation cases across multiple MRI manufacturers and field strengths demonstrated that contrast enhancement measurements achieved R² ≥0.94 and DICE ≥0.81, meeting planned acceptance criteria and showing similar accuracy to the predicate. The addition of T1-weighted post-contrast image analysis is a natural extension of the same segmentation principle already proven in the predicate's FLAIR processing, raising no new safety or effectiveness concerns.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →